Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab

Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in. On October 21, Alector announced the topline results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).

The 96-week, double-blind INFRONT-3 trial, developed in collaboration with GSK, did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR plus NACC FTLD-SB).

In collaboration with GSK, nivisnebart (AL101/GSK4527226) is being evaluated in the PROGRESS-AD, a global, 76-week Phase 2 clinical trial for individuals with early Alzheimer’s disease/AD. Enrollment was completed in April 2025, with trial completion expected in 2026 and an independent interim analysis planned for H1 2026.

Alector Inc. (NASDAQ:ALEC) is a late-stage clinical biotechnology company that develops therapies to counter the devastating progression of neurodegenerative diseases.

While we acknowledge the potential of ALEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.